Bio-Techne stock holds steady as Stifel maintains $60 price target

Investing.com - Stifel maintained its Hold rating and $60.00 price target on Bio-Techne Corp. (NASDAQ:TECH), currently trading at $52.80, following investor meetings with the company’s leadership earlier this week. According to InvestingPro data, the stock trades at a P/E ratio of 63.37, suggesting a premium valuation.

The research firm reported that Bio-Techne’s management conveyed a "fairly constructive" tone regarding factors within the company’s control, while acknowledging ongoing "big-picture headwinds" affecting the sector. This cautious outlook aligns with InvestingPro data showing six analysts recently revising their earnings expectations downward.

Stifel noted that Bio-Techne’s pharmaceutical segment appears positioned to finish the year with mid-single-digit growth, while its Analytical & Genomics (A&G) division remains soft but is likely performing better than competitors in the same space.

The company’s management expressed confidence that the business will re-accelerate and continues to see a path to growth exceeding industry peers by more than 500 basis points, according to Stifel’s research note.

Stifel indicated that while such outperformance appears unlikely to materialize in fiscal year 2026, the composition of Bio-Techne’s portfolio and several trends suggest "some level of out-performance could materialize if the macro factors align."

In other recent news, Bio-Techne Corp. reported its third-quarter earnings for 2025, revealing an adjusted earnings per share (EPS) of $0.56, which exceeded the forecasted $0.51. However, the company’s revenue slightly missed expectations, recording $316.2 million compared to the projected $317.5 million. Despite the revenue miss, the Protein Sciences segment showed robust growth with a 7% organic revenue increase. Benchmark analysts have maintained a Buy rating for Bio-Techne, setting a price target of $75, although they have adjusted their revenue and earnings estimates for the fourth quarter of fiscal year 2025 due to the impact of U.S. tariffs and potential NIH funding cuts.

Wells Fargo (NYSE:WFC) initiated coverage on Bio-Techne with an Overweight rating and a $59 price target, citing the company’s strong financial position and potential for strategic acquisitions, including a significant purchase in 2028. The firm anticipates Bio-Techne could achieve a net cash status by the second half of 2026. Bio-Techne’s challenges include a mid-single-digit revenue decline in the Chinese market and anticipated slower organic growth in the fourth quarter. The company is working to mitigate tariff impacts by fiscal 2026, with expectations of gaining clarity on NIH funding and tariffs in the coming months.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.